SCHEMBL207142

SCHEMBL207142

CCCCCOc1ccc(NC(=O)c2nc(-c3cccnc3)cs2)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.49
MEN1 O00255 2/20 0.43
RAB9A P51151 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
ROCK2 O75116 1/20 0.43
PDGFRA P16234 2/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
KIT P10721 1/20 0.42
KDR P35968 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 1/20 0.41
SGMS2 Q8NHU3 2/20 0.41
ABL1 P00519 2/20 0.41
PDGFRB P09619 1/20 0.41
SRC P12931 1/20 0.41
PRKCA P17252 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705237 0.87 RAB9A (0.43) MEN1RAB9AKMT2AMAPTNR1H4
SCHEMBL206332 0.86 IRAK4 (0.56) S1PR1RAB9AMAPTROCK2NPC1
SCHEMBL204452 0.84 MEN1 (0.57) MEN1RAB9AKMT2AMAPTSMN1; SMN2
SCHEMBL206853 0.84 MEN1 (0.56) MEN1RAB9AKMT2AMAPTSMN1; SMN2
SCHEMBL206765 0.84 MEN1 (0.56) MEN1RAB9AKMT2AMAPTSMN1; SMN2
SCHEMBL207521 0.83 RAB9A (0.54) MEN1RAB9AKMT2AMAPTTDP1
SCHEMBL207156 0.82 MEN1 (0.61) MEN1RAB9AKMT2AMAPTSMN1; SMN2
SCHEMBL2870938 0.80 IRAK4 (0.47) S1PR1MEN1RAB9AKMT2AROCK2
SCHEMBL4655611 0.80 S1PR1 (0.41) S1PR1MEN1RAB9AKMT2AMAPT
SCHEMBL204820 0.79 SGMS2 (0.47) S1PR1MEN1KMT2ASGMS2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 S1PR1 1259/4885MEN1 3862/4885RAB9A 1357/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 S1PR1 1259/4885MEN1 3862/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.